Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof
US11884653B2 · kind B2 · utility
0Cited by
1References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 6, 2021 |
| Grant date | Jan 30, 2024 |
| Priority date | — |
| Expiry date | Apr 6, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D407/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to series novel arylnaphthalene compounds, having a formula (I) or a pharmaceutically acceptable salt thereof, as a vacuolar-ATPase inhibitor that are useful for the treatment for a broad spectrum of viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.